DE60031973T2 - Verfahren zur bilderzeugung durch magnetische resonanz - Google Patents
Verfahren zur bilderzeugung durch magnetische resonanz Download PDFInfo
- Publication number
- DE60031973T2 DE60031973T2 DE60031973T DE60031973T DE60031973T2 DE 60031973 T2 DE60031973 T2 DE 60031973T2 DE 60031973 T DE60031973 T DE 60031973T DE 60031973 T DE60031973 T DE 60031973T DE 60031973 T2 DE60031973 T2 DE 60031973T2
- Authority
- DE
- Germany
- Prior art keywords
- blood
- contrast agent
- relative
- filled
- image
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 66
- 230000005291 magnetic effect Effects 0.000 title claims description 22
- 238000003384 imaging method Methods 0.000 title description 17
- 230000008569 process Effects 0.000 title description 6
- 239000002872 contrast media Substances 0.000 claims abstract description 44
- 238000012800 visualization Methods 0.000 claims abstract description 28
- 210000005166 vasculature Anatomy 0.000 claims abstract description 12
- 239000008280 blood Substances 0.000 claims description 65
- 210000004369 blood Anatomy 0.000 claims description 65
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 31
- 239000000126 substance Substances 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 9
- 239000013307 optical fiber Substances 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 5
- 239000002889 diamagnetic material Substances 0.000 claims description 5
- 239000002907 paramagnetic material Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 3
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical group [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 claims description 3
- 230000014207 opsonization Effects 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 241000271566 Aves Species 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 235000013980 iron oxide Nutrition 0.000 description 16
- 238000002595 magnetic resonance imaging Methods 0.000 description 15
- 230000005298 paramagnetic effect Effects 0.000 description 11
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229910052688 Gadolinium Inorganic materials 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000013522 chelant Substances 0.000 description 7
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000013152 interventional procedure Methods 0.000 description 5
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005293 ferrimagnetic effect Effects 0.000 description 3
- 230000005294 ferromagnetic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 238000010317 ablation therapy Methods 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 230000005292 diamagnetic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229910003440 dysprosium oxide Inorganic materials 0.000 description 2
- NLQFUUYNQFMIJW-UHFFFAOYSA-N dysprosium(iii) oxide Chemical compound O=[Dy]O[Dy]=O NLQFUUYNQFMIJW-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000005415 magnetization Effects 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920001282 polysaccharide Chemical class 0.000 description 2
- 239000005017 polysaccharide Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000007794 visualization technique Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/285—Invasive instruments, e.g. catheters or biopsy needles, specially adapted for tracking, guiding or visualization by NMR
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/281—Means for the use of in vitro contrast agents
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9911937.2A GB9911937D0 (en) | 1999-05-21 | 1999-05-21 | Method |
| GB9911937 | 1999-05-21 | ||
| GB0007869 | 2000-03-31 | ||
| GB0007869A GB0007869D0 (en) | 1999-05-21 | 2000-03-31 | Method |
| PCT/GB2000/001963 WO2000072032A1 (en) | 1999-05-21 | 2000-05-22 | Method of magnetic resonance imaging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60031973D1 DE60031973D1 (de) | 2007-01-04 |
| DE60031973T2 true DE60031973T2 (de) | 2007-09-13 |
Family
ID=26244006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60031973T Expired - Lifetime DE60031973T2 (de) | 1999-05-21 | 2000-05-22 | Verfahren zur bilderzeugung durch magnetische resonanz |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1181570B1 (enExample) |
| JP (1) | JP5426058B2 (enExample) |
| AT (1) | ATE346313T1 (enExample) |
| AU (1) | AU5086000A (enExample) |
| DE (1) | DE60031973T2 (enExample) |
| WO (1) | WO2000072032A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7623903B2 (en) * | 2002-05-17 | 2009-11-24 | Wacker Frank K | Double contrast technique for MRI-guided vascular interventions |
| US7596402B2 (en) * | 2003-05-05 | 2009-09-29 | Case Western Reserve University | MRI probe designs for minimally invasive intravascular tracking and imaging applications |
| JP4807833B2 (ja) * | 2003-10-07 | 2011-11-02 | 株式会社日立メディコ | 磁気共鳴イメージング装置及びこれを用いた造影アンジオグラフィー法 |
| US20100040544A1 (en) * | 2006-11-21 | 2010-02-18 | Anne Waaler | Method for managing patients with cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4310993A1 (de) * | 1993-04-03 | 1994-10-06 | Philips Patentverwaltung | MR-Abbildungsverfahren und Anordnung zur Durchführung des Verfahrens |
| CA2188292A1 (en) * | 1994-04-20 | 1995-11-02 | Larry Margerum | Contrast agents |
| US5479925A (en) * | 1994-06-23 | 1996-01-02 | General Electric Company | Magnetic resonance (MR) angiography in a low-field imaging magnet |
| GB9514877D0 (en) * | 1995-07-20 | 1995-09-20 | Marconi Gec Ltd | Magnetic resonance methods and apparatus |
| US5609153A (en) * | 1995-09-27 | 1997-03-11 | General Electric Company | Magnetic resonance (MR) angiography using a toroidal polarizing magnet and a low-field imaging magnet |
| ES2239349T3 (es) * | 1996-01-10 | 2005-09-16 | Amersham Health As | Medio de contraste. |
| JP3117188B2 (ja) * | 1996-05-30 | 2000-12-11 | 友佑 野々村 | Ｍｒｉ装置 |
| GB9716365D0 (en) * | 1997-08-01 | 1997-10-08 | Nycomed Imaging As | Improvements in or relating to magnetic resonance imaging |
-
2000
- 2000-05-22 DE DE60031973T patent/DE60031973T2/de not_active Expired - Lifetime
- 2000-05-22 EP EP00935306A patent/EP1181570B1/en not_active Expired - Lifetime
- 2000-05-22 AU AU50860/00A patent/AU5086000A/en not_active Abandoned
- 2000-05-22 JP JP2000620368A patent/JP5426058B2/ja not_active Expired - Lifetime
- 2000-05-22 AT AT00935306T patent/ATE346313T1/de not_active IP Right Cessation
- 2000-05-22 WO PCT/GB2000/001963 patent/WO2000072032A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ATE346313T1 (de) | 2006-12-15 |
| JP2003500132A (ja) | 2003-01-07 |
| DE60031973D1 (de) | 2007-01-04 |
| JP5426058B2 (ja) | 2014-02-26 |
| EP1181570A1 (en) | 2002-02-27 |
| EP1181570B1 (en) | 2006-11-22 |
| AU5086000A (en) | 2000-12-12 |
| WO2000072032A1 (en) | 2000-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69433219T2 (de) | Magnetresonanz-Arteriographie mit dynamischer, intravenöser Kontrastmittelinjektion | |
| DE69630245T2 (de) | System zur Abbildung von Arterien mittels magnetischer Resonanz unter Verwendung eines Kontrastmittels für die magnetische Resonanz | |
| DE69427931T2 (de) | Verfahren zur Bilderzeugung mittels magnetischer Resonanz von geänderten Dipolmomenten | |
| DE102010020350B4 (de) | Verfahren zur Positionierung des Fokus eines Gradientenfeldes und Behandlungsvorrichtung | |
| EP0619498B1 (de) | MR-Abbildungsverfahren und Anordnung zur Durchführung des Verfahrens | |
| DE69920425T2 (de) | Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter | |
| DE69332952T2 (de) | Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere | |
| DE69716069T2 (de) | Verfahren zur elektronspinresonanz-verstärkten magnetresonanzabbildung (esremri) mit dynamischer ex vivo kernpolarisation einer magnetresonanzabbildungssubstanz | |
| DE69608181T2 (de) | Verfahren und Gerät für die magnetische Resonanz | |
| US20060293581A1 (en) | Marker device for X-ray, ultrasound and MR imaging | |
| DE19711610A1 (de) | Magnetresonanz-kompatible Kohlefaser-Instrumente | |
| DE3688799T2 (de) | Biologisch abbaubare Mikrokugeln und Verfahren zu deren Herstellung. | |
| EP1115004A2 (de) | MR-Anordnung und MR-Verfahren zur Lokalisierung und/oder Visualisierung eines mit einer passiven Magnetvorrichtung ausgestatteten medizinischen Instruments | |
| DE102010022926A1 (de) | Mikrokapsel zur lokalen Behandlung eines Tumors, Verfahren zur Positionierung eines magnetische Nanopartikel an einen Zielort führenden und/oder an dem Zielort haltenden magnetischen Gradientenfeldes und Vorrichtung zur Positionierung eines magnetischen Gradientenfeldes | |
| DE69827263T2 (de) | Kontrastmittelverstärkte magnetresonanzbildgebung der perfusion von gewebe | |
| EP0742724A1 (de) | Mittel zur visuellen markierung von körpergewebe | |
| JP2003500136A5 (enExample) | ||
| WO2007065935A1 (de) | Wässrige dispersion von superparamagnetischen eindomänenteilchen, deren herstellung und verwendung zur diagnose und therapie | |
| DE69717269T2 (de) | T1-zeitgewichteten kernspintomogram der res-orgäne | |
| US11730831B2 (en) | Imaging agents and methods of using the same | |
| DE60031973T2 (de) | Verfahren zur bilderzeugung durch magnetische resonanz | |
| Duncan et al. | High-resolution magnetic resonance imaging of experimental spinal cord injury in the rat | |
| EP2005970A1 (de) | Bildgebende Diagnostik durch Kombination von Kontrastmitteln | |
| DE60311142T2 (de) | Verfahren für die magnetische resonanzbildgebung | |
| DE60026743T2 (de) | Verwendung von Kontrastmitteln zur Herstellung eines Diagnostischen Mittels für die Darmlumenbildgebung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: HAMMONDS LLP, LONDON, GB |
|
| R082 | Change of representative |
Ref document number: 1181570 Country of ref document: EP Representative=s name: J D REYNOLDS & CO., GB |